SLC9A3R1 Promotes Bladder Cancer Progression Through Regulation of Malignant Phenotypes: Integrated Bioinformatics Analysis and Experimental Validation.
Nov 2026· Cancer Investigation· pp.
1-16
· 0 citations· 36 references
Medicine
TL;DR
SLC9A3R1 may promote bladder cancer progression through mTOR signaling and represents a potential prognostic biomarker and therapeutic target via differential expression, enrichment, and CIBERSORT analyses.
Abstract
Background
SLC9A3R1 is a PDZ domain-containing scaffolding protein, but its role in bladder cancer remains unclear.
Methods
This study analyzed publicly available pan-cancer datasets to characterize the expression patterns and prognostic significance of SLC9A3R1, and further explored its associated biological processes, pathways, and immune cell infiltration via differential expression, enrichment, and CIBERSORT analyses. Functional knockdown experiments in bladder cancer cell lines were also performed to assess the impact of SLC9A3R1 silencing on mTOR signaling and cellular activities.
Results
SLC9A3R1 was abnormally expressed across multiple tumor types, and its prognostic value differed among tumors. High SLC9A3R1 expression was linked to worse clinical outcomes in several distinct bladder cancer cohorts. SLC9A3R1-associated gene profiles were linked to immunological control, metabolic activities, cell cycle regulation, DNA replication and repair, and epithelial differentiation, according to functional enrichment analysis. CIBERSORT analysis further revealed associations between SLC9A3R1 expression and the infiltration levels of multiple immune cell populations in bladder cancer. SLC9A3R1 knockdown was shown to inhibit bladder cancer cell migration and proliferation in vitro, along with decreased levels of p-mTOR and p-S6.
Conclusions
SLC9A3R1 may promote bladder cancer progression through mTOR signaling and represents a potential prognostic biomarker and therapeutic target.
SLC12A7 may promote malignant phenotypes in GC cells through an Ezrin-associated PI3K/AKT signaling mechanism, supporting its potential value as a biomarker and therapeutic target in GC.
Zhi-Jian Li, Shuo Li, Tang-Yi Xiao et al.· Frontiers in Cell and Develo...· 0 citations
Colorectal cancer (CRC) is one of the most common malignancies worldwide, and the prognosis of patients with metastatic disease remains poor. Solute carrier proteins participate in diverse cellular processes, yet the biological and clinical relevance of the SLC35D family in CRC remains largely unexplored. This study sy...
Yu Chang, Kuei-Yen Tsai, C. N. Zumbi et al.· International Journal of Mol...· 0 citations
BACKGROUND
Dysregulated expression of Solute Carrier Family 11 Member 1 (SLC11A1) has been found to be dysregulated in multiple human cancers and is implicated in tumor progression. However, the precise functions and underlying mechanisms of SLC11A1 in hepatocellular carcinoma (HCC) remains largely unknown.
METHODS
T...
Rui-Yao Zhou, Li-Min Ruan, Chao-Hui Wu et al.· Pathology, Research and Prac...· 0 citations
INTRODUCTION
SLC7A11 is part of the solute carrier family and encodes the transporter xCT. However, its functional role in renal cell carcinoma (RCC) progression and associated tumor microenvironment (TME) modulation remains poorly characterized and requires further investigation. This study aimed to explore SLC7A11 ex...
Xin-Yang Cheng, Jun Zhang, Ji-Xin Yuan et al.· Current Medicinal Chemistry· 0 citations
BACKGROUND
This study aimed to investigate the expression patterns, immunological functions, and prognostic value of LINC00942 across multiple cancer types, and to further examine its role in chemoresistance.
METHODS
LINC00942 expression and its diagnostic and prognostic significance were analyzed across 33 cancer ty...
Tetratricopeptide repeat domain protein 39B (TTC39B) is a lipid metabolism–related gene recently implicated in cholesterol regulation. However, its clinical and biological relevance in human cancers remains undefined.
Based on multi-omics data from the Cancer Genome Atlas (TCGA) pan-cancer dataset represen...
Hui-Juan Yi, Yan Wang, Chen-Hao Zhao et al.· BMC Medical Genomics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.